December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS). 

December 14, 2022 —  Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of-its-kind, purpose built, focal pulsed field ablation (PFA) therapy integrated seamlessly with 3D mapping & navigation.  

Both teams will harness decades of experience in pioneering novel PFA and navigation product solutions in various medical therapy applications. 

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, “12 Days of Carotid Stenting,” which will feature leading multidisciplinary vascular specialists discussing the current and future trends in the carotid treatment market. The series will be available for viewing beginning on Monday, November 28, 2022. 

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without standard modifiable heart risk factors who experience a heart attack are common and more likely to fare better than heart-attack patients with known risk factors, but researchers

December 12, 2022 —  Edwards Lifesciences Corporation announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A.